Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05200273
Other study ID # AK114-102
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date March 15, 2022
Est. completion date December 30, 2023

Study information

Verified date January 2022
Source Akeso
Contact Alex HL Wong, MMedSc
Phone +86(0760)89873999
Email global.trials@akesobio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.


Description:

This is a first-in-human (FIH), Phase 1a, multicenter, open-label, single-arm dose-escalation study of AK114 to evaluate the safety, tolerability, PK, pharmacodynamics, antitumor activity and immunogenicity in adult subjects with advanced or metastatic solid tumors. The study is comprised of dose escalation phase. Approximately 30 subjects will be treated in this study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 30, 2023
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written and signed informed consent 2. Age = 18 3. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor 4. Subject must have at least one measurable lesion according to RECIST v1.1 5. Eastern Cooperative Oncology Group (ECOG) performance status score = 1 6. At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must have been treated 7. Available archived tumor tissue sample (block or a minimum of 10 unstained slides of formalin-fixed paraffin-embedded tissues) to allow for correlative biomarker studies 8. Subjects may opt to provide two fresh biopsy samples (pretreatment and on treatment), where clinically appropriate 9. Adequate organ function 10. Use acceptable method of contraception from screening, and must agree to continue for 120 days after the final dose of investigational product Exclusion Criteria: 1. History of severe hypersensitivity reactions to other monoclonal antibodies 2. History or concurrent gastrointestinal perforation, surgery and wound healing complications, hemorrhage events 3. Patients with clinically significant cardiovascular disease 4. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of investigational product administration 5. Active or prior documented autoimmune disease within the past 2 years 6. History of primary immunodeficiency 7. History of organ transplant or hematopoietic stem cell that requires use of immunosuppressive medications 8. Known allergy or reaction to any component of the investigational product formulation. 9. History of interstitial lung disease or noninfectious pneumonitis except for those induced by radiation therapies. 10. Prior treatment with canakinumab.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AK114
AK114 administered by subcutaneous injection

Locations

Country Name City State
Australia Ashford Cancer Centre Kurralta Park South Australia

Sponsors (1)

Lead Sponsor Collaborator
Akeso

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events (AEs) An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study drug, whether or not considered related to the study drug. From the time of informed consent signed through to 90 days after last dose of study drug
Primary Number of participants with a Dose Limiting Toxicity (DLTs) DLTs will be assessed as having a suspected relationship to study drug according to pre-specific criteria in the protocol. Within the first 28 days after receiving the first dose of study drug
Secondary Serum pharmacokinetics (PK) Serum concentrations of study drug in individual subjects at different time points after study drug administration From first dose of treatment through to 90 days after end of treatment
Secondary Number of subjects who develop detectable anti-drug antibodies (ADAs) The immunogenicity of study drug will be assessed by summarizing the number of subjects who develop detectable ADAs. From first dose of study drgu through to 90 days after end of treatment
Secondary Objective response rate (ORR) The ORR is defined as the proportion of subjects with confirmed complete response (CR) or confirmed partial response (PR), based on RECIST Version 1.1. Up to 2 years
Secondary Disease control rate (DCR) DCR is defined as the number (%) of subjects with best of response of confirmed CR or PR, or stable disease (SD) according to RECIST v1.1. Up to 2 years
See also
  Status Clinical Trial Phase
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Completed NCT01206530 - FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Phase 1/Phase 2
Completed NCT01199822 - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors Phase 1
Completed NCT00313859 - Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC Phase 2
Completed NCT00377936 - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT05095207 - Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT04392479 - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. Phase 3
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Terminated NCT03652493 - Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT05061082 - Genomic Evolution of Metastasis in Gastric Cancer
Not yet recruiting NCT06055764 - Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
Terminated NCT02796729 - CEST- Glucose Enhanced MRI for Metastatic Brain Tumours Phase 2
Withdrawn NCT01157039 - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin Phase 2
Terminated NCT01000948 - A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer Phase 2
Terminated NCT01613482 - TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention Phase 3
Withdrawn NCT00244348 - Hepatic Artery Infusion With Oxaliplatin Phase 1/Phase 2
Recruiting NCT04416165 - Comparison of FDG and FAPI in Patients With Various Types of Cancer N/A